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patient with metastatic castration-resistant
prostate cancer treated with radium-223,
a case report
Megan A McNamara1,2* and Daniel J George1,3Abstract
Background: Radium-223 has been shown to improve overall survival in men with metastatic castration-resistant
prostate cancer with symptomatic bone metastases. The bone scan response to radium-223 has only been described
in one single center trial of 14 patients, none of whom achieved the outstanding bone scan response presented in the
current case.
Case presentation: In this case report, we describe a 75 year-old white man with extensively pre-treated metastatic
castration-resistant prostate cancer and symptomatic bone metastases who experienced a flare in pain and
prostate-specific antigen, followed by dramatic clinical (pain), biochemical (prostate-specific antigen), and imaging
(bone scan) response.
Conclusion: The flare phenomena and bone scan response we observed have not previously been described with
radium-223. This case suggests that the degree and duration of bone scan response may be predictive of overall
survival benefit.
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Prostate cancer is the most common non-cutaneous
malignancy in US men and is the second leading cause
of cancer-related mortality [1]. In 2014, it is estimated that
29,480 men died from metastatic castration-resistant
prostate cancer (mCRPC), the terminal form of the
disease. Among patients with mCRPC, bone is the most
frequent site of metastatic disease. These metastases are
characterized by high uptake of technetium phosphate on
bone scan and represent calcium deposition in areas of
osteoblastic-driven bone turnover. Bone metastases cause
significant morbidity, including pain requiring palliative
radiation, pathologic fractures, spinal cord compression, and
orthopedic surgery, otherwise referred to as symptomatic* Correspondence: Megan.diehl@duke.edu
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article, unless otherwise stated.skeletal events (SSE) [2-4], and are independently associated
with increased mortality in patients with mCRPC [5].
Radium-223 dichloride (Radium-223, Xofigo, previously
alpharadin) is a first-in-class alpha-emitting radionuclide,
approved for the treatment of men with mCRPC with
symptomatic bone metastases and no known visceral
metastases. It acts as a calcium-mimetic and is preferentially
taken up into areas of high bone turnover, such as those
surrounding bone metastases [6,7]. Once radium-223
reaches bone, it emits alpha-particle radiation, which
induces double stranded breaks in DNA, causing a local
cytotoxic effect [6,8]. Importantly, because alpha particles
have a very short range (<100 μm), there is limited damage
to surrounding normal tissues, including bone marrow
[7,9]. In early drug testing, radium-223 was given safely with
repeated dosing every four weeks [10-14].
A randomized phase III clinical trial (ALSYMPCA,
alpharadin in symptomatic prostate cancer) demonstrated
that treatment with radium-223 every four weeks for uped Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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with mCRPC with bone metastases, compared to placebo
[4], leading to FDA approval in this setting in May 2013.
This survival benefit distinguishes radium-223 from
other therapies, including local radiation, radioisotopes
strontium-89 and samarium-153, zoledronic acid, and
denosumab, which have been shown to decrease pain from
bone metastases but have not shown an improvement in
overall survival [15-17]. The ALSYMPCA trial also
demonstrated that treatment with radium-223 prolonged
the time to first symptomatic skeletal event, improved
alkaline phosphatase, enhanced quality of life, and was
well tolerated. A prostate-specific antigen (PSA) response
was observed in a minority of patients [4].
Interestingly, the bone scan response to treatment
with radium-223 was not described in the ALSYMPCA
trial. In fact, there is currently no validated method to
quantify decreased tumor burden on bone scan, and to
our knowledge, the bone scan response to radium-223 has
only been described in one single center trial of 14
patients, in which bone scans were obtained at baseline
and one month after the 6th dose of radium-223. In
this study, bone scans were manually reviewed by two
radiologists, who counted the number of new metastatic
lesions and scored the bone scans according to the
Soloway extent of disease classification. After treatment
with radium-223, most patients in this study (10 of 12
evaluable) demonstrated decreased radiotracer uptake in
existing lesions. However, new areas of uptake, consistent
with new osseous metastatic lesions, developed in 11 of 12
of these patients [18].
The following case report presents a 75 year-old
otherwise-healthy white male, who presented withFigure 1 PSA trend and response to radium-223. The trend in the patient’s
radium-223 is highlighted. PSA flared after the first dose of radium-223, pea
steadily improved and nadired at 554 ng/mL about 1 month after the 6th
stable at about 600 ng/mL for about 7 months before increasing again.metastatic prostate cancer with a single, asymptomatic
osseous metastasis. He was extensively treated with
androgen deprivation therapy, combined androgen
blockade, immunotherapy with sipuleucel-T, docetaxel
chemotherapy, enzalutamide, and palliative external beam
radiation, with varying degree and duration of response.
He eventually developed mCRPC with symptomatic,
widespread osseous metastases and was treated with
radium-223, with an initial flare in pain and PSA, followed
by dramatic and durable improvement in pain, alkaline
phosphatase, and bone scan.
Case presentation
Our patient first presented in February 2008 with lower
urinary tract symptoms and was found to have an
elevated PSA at 14.8 ng/mL (Figure 1). Subsequent
transrectal ultrasound-guided biopsy of the prostate
showed high-grade prostate adenocarcinoma, with
Gleason Score 4 + 5 = 9 and 4 + 4 = 8, in 10 of 13 cores, in
all areas of the prostate. Because of the high-grade disease,
staging studies were performed. Bone scan showed
increased uptake in the left pubic ramus (Figure 2A).
CT scan of the abdomen and pelvis did not show
lymphadenopathy or intraabdominal disease but did
demonstrate blastic activity in the left superior pubic
ramus, corresponding to the region of increased uptake
seen on bone scan. Overall, this presentation was felt to
be consistent with metastatic prostate cancer with a single,
asymptomatic, bone metastasis.
In June 2008, he was initiated on androgen deprivation
therapy (ADT), which he has remained on, with or without
additional therapies, since then. Please refer to Table 1 for
full details of his treatment course prior to radium-223.PSA over the course of his disease is shown, and the PSA response to
king at 996 ng/mL 3 weeks after the initiation of therapy. PSA then
dose of radium-223. After completion of radium-223, PSA remained
Figure 2 Radionuclide bone scan trend and response to radium-223. A. June 2008, metastatic prostate cancer diagnosis. B. May 2010, disease
progression on combined androgen blockade. C. May 2011, disease progression following sipuleucel-T immunotherapy. D. December 2011,
disease progression just prior to docetaxel chemotherapy. E. June 2013, widespread disease progression associated with severe diffuse bone
pain on enzalutamide (“pre-radium-223”). F. February 2014, dramatic bone scan response two months after completing six treatments of
radium-223 (“post-radium-223”).
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DHEAS inhibitor on a Phase I clinical trial, sipuleucel-T
immunotherapy, a CYP17 inhibitor plus prednisone on a
Phase III clinical trial, 10 cycles of docetaxel chemotherapy
plus prednisone, and enzalutamide, as well as two courses
of palliative radiation to painful osseous metastases. He
had transient improvement in his mCRPC in response to
many of these therapies, but overall his course was charac-
terized by disease progression, with rising PSA, increasing
alkaline phosphatase, and growing osseous metastases.
By July 2013, PSA had reached 653 ng/mL (Figure 1)
and alkaline phosphatase was 564 U/L (Figure 3). He
had also developed severe diffuse bone pain. Re-staging
scans showed disease progression with increase in the
size of diffuse bone metastases, some of which were now
confluent (Figure 2E). There was still no evidence of
visceral metastatic disease.
On August 1, 2013, he received his first dose of
radium-223 50 kBq/kg. Enzalutamide (and leuprolide)
were continued. Following the first dose of radium-223,he experienced a flare in his bone pain, which he
described as “severe, total body pain” that caused him to
be bedbound for 10 days. A concurrent flare in PSA was
also observed, with PSA peaking at 996 ng/mL three
weeks after the first dose of radium-223 (Figure 1). After
the initial flare, bone pain and PSA steadily improved.
He was able to discontinue opioids within eight weeks of
start of therapy. After his fifth dose of radium-223, he
developed symptomatic anemia with hemoglobin 7.5 g/dL.
He was transfused two units of packed red blood cells and
has remained red blood cell transfusion-dependent since
then, requiring transfusions every two to four weeks. He
completed his sixth dose of radium-223 in December
2013. PSA nadired at 554 ng/mL in January 2014
(Figure 1). Alkaline phosphatase dropped steadily
throughout the course of radium-223 and nadired at
144 U/L in January 2014 (Figure 3). Re-staging bone
scan in February 2014 showed a dramatic response to
radium-223 with significant decrease in activity of all
skeletal metastases (Figure 2F).
Table 1 Timeline
Date PSA (ng/mL) Imaging Bone pain level Therapy
February 2008 14.8 Single bone metastasis in
left pubic ramus
None
June 2008 20.1 None ADT initiated
October 2008 0.2 None
June 2010 8.0 Progression: increase in the
extent of abnormal radiotracer
activity within the left acetabulum
and left superior pubic ramus
None Phase I study of BN83495 (DHEAS
inhibitor)
July 2010 13 Moderate Taken off study for PSA progression;
Palliative radiation to pelvic bone




February 2011 Progression: new osseous metastases;
no visceral metastases
None
April 2011 54.8 None
May 2011 Progression: new osseous metastases;
no visceral metastases
None
June 2011 None Phase III study of CYP17 inhibitor
plus prednisone (randomized to
CYP17 inhibitor arm)
October 2011 126.4 Progression: new osseous metastases;
no visceral metastases
Moderate Taken off study for symptomatic
disease progression
January 2012-July 2012 234 (January)
46.95 (July)




Stable osseous metastatic disease;
no visceral metastases
Mild
December 2012 128 Moderate Palliative radiation to a sacral osseous
metastasis for low back pain
January 2013 331 Mild Enzalutamide initiated
February 2013 224 Mild
July 2013 653 Progression of osseous metastatic
disease; no visceral metastases
Severe diffuse bone pain
August 2013 996 Pain flare for 10 days after
1st dose of radium-223
1st dose of radium-223
October 2013 Pain significantly improved,
discontinued opioids





December 2013 Mild pain controlled
with NSAIDs
6th dose radium-223
January 2014 554 Mild pain controlled
with NSAIDs
February 2014 Dramatic bone scan response to
radium-223 with significant decrease
in activity of all skeletal metastases
Mild pain controlled
with NSAIDs




July 2014 780 Out-of-field disease progression:
new diffuse osseous metastases




Steroids and stereotactic radiation
to skull base mass
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Figure 3 Alkaline phosphatase trend and response to radium-223. The trend in the patient’s alkaline phosphatase over the course of his disease
is shown, and the alkaline phosphatase response to radium-223 is highlighted. Alkaline phosphatase was 564 U/L at the time of initiation of
radium-223 and steadily improved throughout the course of radium-223. Alkaline phosphatase nadired at 144 U/L about 1 month after the 6th
dose of radium-223 and then trended up again.
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with continued pain relief, requiring only as-needed
NSAIDs, and stable PSA of about 600 ng/mL until July
2014 (Figure 1), when he reported new right temporal
headache and diplopia. Brain MRI at that time showed
interval development of new diffuse osseous metastatic
disease in the skull, not present at the time of radium,
with intracranial and intraorbital mass extension, exerting
mass effect on the lateral rectus and optic nerve. Bone
scan confirmed the MRI findings and showed no change
in the appearance of his previously existing metastatic
disease. PSA had increased to 780 ng/mL (Figure 1).
He was started on steroids and underwent stereotactic
radio-surgery (SRS) to the skull base mass, with resolution
of his headaches and diplopia.
Conclusions
There are four unique features of this case that have not
been well described in the literature. First, the pain flare
phenomenon that our patient experienced has only been
reported in a Phase I trial of radium-223, in which seven
of twenty-five patients had a “flare” in pain during the
first week of radium-223 treatment [11]. In our case,
the pain flare involved multiple sites and resulted in a
transient decrease in performance status that lasted
10 days. Subsequent radium-223 doses were associated
with much less or no pain flare.
Second, the PSA flare phenomenon that we observed
has not been described following treatment with
radium-223. In our clinical experience, other forms of
radiotherapy have also been associated with a transient
increase in PSA. We hypothesize that the observed PSA
flare after radium-223 treatment is due to PSA releasefrom tumor cell lysis. Based on this mechanism of action
and on our experience with this patient, PSA flare may
correspond to a high degree of tumor cell kill and may
be associated with more complete and more durable
response to radium-223.
Third, we are aware of one other case report that
includes a dramatic bone scan response to radium-223,
similar to what we observed in our patient [19]. As
mentioned previously, in the only study to date that has
described the bone scan response to radium-223, the
majority of patients experienced decreased radiotracer
uptake in existing bone lesions with simultaneous
development of new osseous metastatic lesions. None of
the patients in that study demonstrated the excellent bone
scan response that we saw in our patient. Additionally,
that study included only a single post-radium-223 bone
scan, so the duration of response in those patients is
unknown [18]. This is in contrast to our patient, who
maintained his outstanding response for seven months
after completion of radium-223.
Finally, anemia is a known poor prognostic factor in
mCRPC and a known side effect of radium-223. Red
blood cell transfusions are required in about twice as
many patients receiving radium-223 with prior docetaxel
use, compared to patients with no prior docetaxel use
[20]. However, continued transfusion dependence in the
absence of continued radium-223 therapy or systemic
disease progression, like we observed in our patient, has
not been described. We attribute our patient’s transfusion
dependence to his high tumor burden and associated
high radium uptake, which resulted in diffuse sclerosis
on CT of his pelvis and other osseous sites (Figure 4).
Prior chemotherapy and radiation therapy likely also
Figure 4 Diffuse sclerosis, resulting from the patient’s high osseous tumor burden and associated high radium-223 uptake. Diffuse osseous
sclerosis on CT imaging of the spine (A), bilateral ilia (B), and bilateral femoral heads (B) is shown. This sclerosis occurred because of the patient’s
high volume of bony metastatic disease and consequential high radium-223 uptake. We believe that this combination of high osseous tumor
burden and high radium-223 uptake, resulting in diffuse sclerosis, contributed to our patient’s transfusion dependence, which has persisted in
the absence of continued radium-223 therapy or systemic disease progression.
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anemia in this patient. Interestingly, this has not affected his
survival (>1 year since becoming transfusion dependent),
likely because it is not from disease progression.
We conclude that treatment of men with mCRPC
with radium-223 can cause a flare in pain and PSA
after the first dose of therapy and can also achieve an
outstanding bone scan response. Additionally, there is
a risk of red blood cell transfusion dependence in
extensively pre-treated patients with high burden of
osseous metastases, which should not necessarily be
viewed as a poor prognostic sign. Knowledge of the
potential for a flare in pain and PSA has implications
for treatment, since it is important to realize that a
flare does not necessarily indicate lack of response to
radium-223 and may in fact be predictive of an excellent
overall response, as demonstrated in our patient. Based on
our experience with this patient, we would recommend
counseling patients beginning radium-223 about the
possibility of pain and PSA flare. In the event that a
pain flare occurs, we suggest pain management with
as needed acetaminophen and oxycodone.
The duration of objective imaging response in this
case and the subsequent progression in new sites of
disease suggests a change in the tumor environment of
the treated disease sites that is more durable, compared
to patients who develop disease progression in existing
disease sites after treatment with radium-223. Furthermore,
based on our experience with this patient, who, at the time
of submission, is still alive 16 months after the first
dose of radium-223, an excellent bone scan response
may be predictive of a better overall survival benefitand should be evaluated in larger series. Transfusion
dependence could be avoided by treating similar patients
with radium-223 earlier in their disease course. Further
studies are needed to better understand the bone scan
response to radium-223.
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